• Product NameDabigatran etexilate
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityDabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.?FDA?approved on October 19, 2010.
• Target NameThrombin inhibitor
• CAS No. 211915-06-9
• Calculated MW 627.73
• Formulation C34H41N7O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\N
  Pathways:Others
  Receptor:Thrombin
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 12 mg/mL (19.11 mM); DMSO: 126 mg/mL (200.72 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Squizzato A, et al. Intern Emerg Med. 2009 Dec;4(6):479-84.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting